NCT02635087|Unknown
Loading search results
Sponsor study identifier
observational
630
1 country
1
Study Start
December 2015
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
July 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The investigators discover the investigators' miRNA tool can be a useful tool to predict the patients with stage II colon who can benefit from chemotherapy.Then the investigators plan to make an observation study that may validation this tool.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2015
Date type not reportedThis date has not been verified as actual or estimated.
December 16, 2015
Actual (reported)December 18, 2015
Actual (reported)July 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
July 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
DFS
3 years
OS
5 years
the miRNA tool predict this group of patients as "high risk"
patients to be assessed by the miRNA tool. MicroRNA tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miR-21-5p)+(0.086×status of miR-20a-5p)+(0.240×status of miR-103a-3p)+(0.095×status of miR-106b-5p)- (0.238×status of miR-143-5p)-(0.237×status of miR-215),low expression status equals 0 and high expression status equals 1.Then we determine the patients who with a score higher than 1 as exposed patient.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
The patients who had stage II colon cancer and received surgery.They agree to use miRNA tool to test their postoperative specimen.
FisrtSunYetsen
Guangzhou, Guangdong, 510000, China
We will use the samples to make q-RT-PCR of our miRNA tool,then predict the patients as high risk one or not.
Wu Song, MD
First Affiliated Hospital, Sun Yat-Sen University
First Submitted
December 16, 2015
First Posted
December 18, 2015
Study Start
December 2015
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
July 2020
Estimated (date passed)The Role of Adding Concurrent Chemotherapy to IMRT in the Treatment of Stage II Nasopharyngeal Carcinoma
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
December 30, 2015
Record last verified: 2015-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: